Gangliogliomas are well differentiated, usually low grade, neuroepithelial tumors that comprise of neoplastic ganglion cells in combination with neoplastic glial cells. Occasionally, glial cells may show anaplastic features and are then labeled as anaplastic gangliogliomas. Most of the reported gangliogliomas are supratentorial tumors, predominantly in the temporal lobe. Brainstem location has been reported infrequently. As with cortically based gangliogliomas, though the primary treatment is resection, this is often not possible due to the eloquence of surrounding involved parenchyma. Here, we report a case of brainstem tumor in an 8-month-old child that was substantially resected and was histopathologically Grade 1 ganglioglioma. As per review of English literature, there has been no case of brainstem ganglioglioma reported in an infant (less than 1 year age). We discuss the surgical difficulties in the radical excision of such benign tumors and review literature on pediatric brainstem gangliogliomas.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3680895PMC
http://dx.doi.org/10.4103/1817-1745.111422DOI Listing

Publication Analysis

Top Keywords

brainstem ganglioglioma
8
review literature
8
glial cells
8
case brainstem
8
brainstem
5
gangliogliomas
5
ganglioglioma infant
4
infant case
4
case report
4
report review
4

Similar Publications

BRAF inhibitor monotherapy in BRAFV600E-mutated pediatric low-grade glioma: a single center's experience.

Front Oncol

January 2025

Department of Pediatrics, Children's Healthcare of Atlanta, Atlanta, GA, United States.

Background: Pediatric low-grade gliomas (pLGGs) have an overall survival of over 90%; however, patients harboring a BRAF alteration may have worse outcomes, particularly when treated with classic chemotherapy. Combined BRAF/MEK inhibition following incomplete resection demonstrated improved outcome in BRAF altered pLGG compared to combined carboplatin/vincristine chemotherapy and is now considered the standard FDA-approved treatment for this group of tumors. The aim herein was to investigate the efficacy and tolerability of single agent BRAF inhibitor treatment in BRAF altered pLGG.

View Article and Find Full Text PDF

The 2021 World Health Organization (WHO) classification of the central nervous system (CNS) tumors has classified diffuse leptomeningeal glioneuronal tumor (DLGNT) as a mixed neuronal and glial tumor. Here, we report a DLGNT with two distinct morphological tumor components but identical molecular features. A four-year-old female child presented with progressive right upper extremity weakness.

View Article and Find Full Text PDF
Article Synopsis
  • NTRK gene fusions occur in about 1% of gliomas and are considered promising targets for treatment due to their ability to cross the blood-brain barrier, leading to interest in TRK inhibitors.
  • A study of 12 NGS-verified NTRK-fused gliomas at Seoul National University Hospital found that DLGGs mostly had only NTRK fusions, while DHGGs often had additional genetic mutations, with various fusion partners identified for NTRK1 and NTRK2.
  • Treatment outcomes using TRK inhibitors varied significantly; one child with DLGG showed stable disease, while a child with DHGG and an adult with glioblastoma experienced tumor recurrence and progression, highlighting the mixed
View Article and Find Full Text PDF

Background: Ganglioglioma (GG) is a slow-growing glioneuronal neoplasm, most frequently seen in the supratentorial location in older children and associated with epilepsy syndromes. GG is rare in the infratentorial location, hence we embarked upon analyzing the National Cancer Institute's (NCI) Survival, Epidemiology, and End Results (SEER) database to better evaluate GG outcomes by location in comparison to the broader pediatric low-grade glioma (pLGG) population.

Methods: Pediatric patients diagnosed with GG and pLGG from 2004 to 2018 were included in the study.

View Article and Find Full Text PDF

Infratentorial Relapsing Neuroglial Tumors in Adults: Management and Unsolved Issues-A Systematic Review.

Brain Sci

March 2024

Neurosurgical Clinic, AOUP (Azienda Ospedaliera Universitaria Policlinico) "Paolo Giaccone", Post Graduate Residency Program in Neurologi Surgery, Department of Biomedicine Neurosciences and Advanced Diagnostics, School of Medicine, University of Palermo, Via del Vespro 127, 90127 Palermo, Italy.

(1) Background: Gangliogliomas are rare tumors accounting for about 0.4% of all central nervous system tumors. They are usually located in the temporal lobes of children and young adults, though such tumors in the infratentorial region and adult-age patients rarely reported.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!